{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:07:02Z","timestamp":1774559222200,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.molimm.2022.02.021","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T22:39:51Z","timestamp":1647038391000},"page":"50-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Viral resistance to VRC01-like antibodies with mutations in loop D and V5 from an HIV-1 B\u2032 subtype infected individual with broadly neutralization activity"],"prefix":"10.1016","volume":"145","author":[{"given":"Dai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Li","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ling","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.molimm.2022.02.021_bib1","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.molimm.2022.02.021_bib2","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.molimm.2022.02.021_bib3","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1172\/JCI134395","article-title":"Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound","volume":"130","author":"Cale","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"7557","key":"10.1016\/j.molimm.2022.02.021_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.molimm.2022.02.021_bib5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.molimm.2022.02.021_bib6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.chom.2017.05.003","article-title":"Comprehensive mapping of HIV-1 escape from a broadly neutralizing antibody","volume":"21","author":"Dingens","year":"2017","journal-title":"Cell Host Microbe"},{"issue":"51","key":"10.1016\/j.molimm.2022.02.021_bib7","doi-asserted-by":"crossref","first-page":"43170","DOI":"10.1074\/jbc.M112.399402","article-title":"A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01","volume":"287","author":"Guo","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.molimm.2022.02.021_bib8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nm.4063","article-title":"Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques","volume":"22","author":"Hessell","year":"2016","journal-title":"Nat. Med."},{"issue":"Pt 10","key":"10.1016\/j.molimm.2022.02.021_bib9","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1099\/vir.0.043802-0","article-title":"Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B\u2032-infected former plasma donors from China naive to antiretroviral therapy","volume":"93","author":"Hu","year":"2012","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.molimm.2022.02.021_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.immuni.2016.03.006","article-title":"Key gp120 glycans pose roadblocks to the rapid development of VRC01-class antibodies in an HIV-1-infected Chinese donor","volume":"44","author":"Kong","year":"2016","journal-title":"Immunity"},{"issue":"6686","key":"10.1016\/j.molimm.2022.02.021_bib11","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.molimm.2022.02.021_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008026","article-title":"Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies","volume":"15","author":"LaBranche","year":"2019","journal-title":"PLOS Pathog."},{"issue":"9","key":"10.1016\/j.molimm.2022.02.021_bib13","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nm1624","article-title":"Broad HIV-1 neutralization mediated by CD4-binding site antibodies","volume":"13","author":"Li","year":"2007","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.molimm.2022.02.021_bib14","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1128\/JVI.00754-11","article-title":"Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01","volume":"85","author":"Li","year":"2011","journal-title":"J. Virol."},{"issue":"7209","key":"10.1016\/j.molimm.2022.02.021_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature07159","article-title":"Molecular architecture of native HIV-1 gp120 trimers","volume":"455","author":"Liu","year":"2008","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.molimm.2022.02.021_bib16","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.1128\/JVI.00734-12","article-title":"The development of CD4 binding site antibodies during HIV-1 infection","volume":"86","author":"Lynch","year":"2012","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.molimm.2022.02.021_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1084\/jem.20122824","article-title":"Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies","volume":"210","author":"McGuire","year":"2013","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.molimm.2022.02.021_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/JVI.77.1.353-365.2003","article-title":"Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies","volume":"77","author":"Poignard","year":"2003","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.molimm.2022.02.021_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004966","article-title":"Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell-cell transmission is strain- and epitope-dependent","volume":"11","author":"Reh","year":"2015","journal-title":"PLOS Pathog."},{"issue":"6525","key":"10.1016\/j.molimm.2022.02.021_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd2638","article-title":"Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth","volume":"371","author":"Roark","year":"2021","journal-title":"Science"},{"issue":"6288","key":"10.1016\/j.molimm.2022.02.021_bib21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.molimm.2022.02.021_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.virol.2020.08.012","article-title":"Characteristics of HIV-1 env genes from Chinese chronically infected donors with highly broad cross-neutralizing activity","volume":"551","author":"Sha","year":"2020","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.molimm.2022.02.021_bib23","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1089\/aid.2017.0063","article-title":"A 2-4-amino acid deletion in the V5 region of HIV-1 Env gp120 confers viral resistance to the broadly neutralizing human monoclonal antibody, VRC01","volume":"33","author":"Tachibana","year":"2017","journal-title":"AIDS Res Hum. Retrovir."},{"issue":"1","key":"10.1016\/j.molimm.2022.02.021_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11684-019-0721-9","article-title":"Broadly neutralizing antibodies and vaccine design against HIV-1 infection","volume":"14","author":"Wang","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.molimm.2022.02.021_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-4690-10-14","article-title":"A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization","volume":"10","author":"Wang","year":"2013","journal-title":"Retrovirology"},{"issue":"3","key":"10.1016\/j.molimm.2022.02.021_bib26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/QAI.0000000000000595","article-title":"N463 glycosylation site on V5 loop of a mutant gp120 regulates the sensitivity of HIV-1 to neutralizing monoclonal antibodies VRC01\/03","volume":"69","author":"Wang","year":"2015","journal-title":"J. Acquir Immune Defic. Syndr."},{"issue":"10","key":"10.1016\/j.molimm.2022.02.021_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003738","article-title":"Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes","volume":"9","author":"Wibmer","year":"2013","journal-title":"PLOS Pathog."},{"key":"10.1016\/j.molimm.2022.02.021_bib28","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3389\/fmicb.2019.01096","article-title":"Characteristics of envelope genes in a Chinese chronically HIV-1 infected patient with broadly neutralizing activity","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Microbiol."},{"issue":"6","key":"10.1016\/j.molimm.2022.02.021_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007819","article-title":"Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies","volume":"15","author":"Zhou","year":"2019","journal-title":"PLOS Pathog."},{"issue":"5993","key":"10.1016\/j.molimm.2022.02.021_bib30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.molimm.2022.02.021_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.immuni.2013.04.012","article-title":"Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies","volume":"39","author":"Zhou","year":"2013","journal-title":"Immunity"}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589022000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589022000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:41:57Z","timestamp":1758980517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589022000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":31,"alternative-id":["S0161589022000505"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2022.02.021","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral resistance to VRC01-like antibodies with mutations in loop D and V5 from an HIV-1 B\u2032 subtype infected individual with broadly neutralization activity","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2022.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}